Search Results
Your search for ,tWo matches 12459 pages
Showing 12301 - 12350U.S. Preventive Services Task Force Recommends Screening for Lung Cancer in High-risk Individuals
The U.S. Preventive Services Task Force posted its final evidence report and draft recommendation statement on screening for lung cancer. The Task Force is providing an opportunity for public comment on this draft recommendation statement; comments can be submitted from July 30 to August ...
Low-dose CT Screening for Lung Cancer: Details of First Round of Screening in National Lung Screening Trial
The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also...
Particulate Matter Air Pollution Contributes to Increased Risk of Lung Cancer in Europe
Ambient air pollution has been associated with lung cancer risk. In a study reported in Lancet Oncology by Ole Raaschou-Nielsen, PhD, of the Danish Cancer Society Research Center, and colleagues, lung cancer incidence in European countries was prospectively assessed according to several measures of ...
No Benefit of Adding Atrasentan to Docetaxel in Advanced Castration-resistant Prostate Cancer
The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer, and the investigational endothelin receptor antagonist atrasentan has shown activity in prostate cancer. In the SWOG S0421 trial reported in Lancet Oncology by David I. Quinn, FRACP, of...
Intratumoral IL-12 Injections Shrink Melanoma and Merkel Cell Tumors
Intratumoral injections of plasmid DNA encoding interleukin-12 (IL-12), facilitated in its delivery by electroporation, results in tumor regression in patients with both metastatic melanoma and Merkel cell carcinoma, according to findings reported at the 2013 World Cutaneous Malignancies Congress...
Digital PCR Technology Detects Brain Tumor–associated Mutation in Cerebrospinal Fluid
Researchers at Massachusetts General Hospital have used digital versions of a standard molecular biology tool to detect a common tumor-associated mutation in the cerebrospinal fluid of patients with brain tumors. In a report published in Molecular Therapy – Nucleic Acids, the...
Study Evaluates Therapeutic Impact of Laparoscopic Para-aortic Staging Surgery before Chemoradiotherapy in Cervical Cancer
In a study reported in Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy, and colleagues evaluated survival outcomes in locally advanced cervical cancer patients with negative PET-CT imaging results who underwent laparoscopic para-aortic staging surgery before...
No Difference in Event-free Survival with Chemotherapy before vs after Radiation Therapy in Children with High-risk Medulloblastoma
A number of different strategies for combining chemotherapy and radiation therapy have been evaluated in the effort to improve survival in patients with high-risk medulloblastoma. In a trial (POG 9031) reported in Journal of Clinical Oncology, Nancy J. Tarbell, MD, of Massachusetts General Hospital ...
Molecular Profiling Improves Classification of Nodal Peripheral T-cell Lymphomas
The differential diagnosis of the most common peripheral T-cell lymphoma subtypes is difficult. In a phase III diagnostic accuracy study reported in Journal of Clinical Oncology, Pier Paolo Piccaluga, MD, PhD, of the University of Bologna, and colleagues in the European T-cell Lymphoma Study Group...
Study Suggests Proteins Involved in Immunity May Be Responsible for Cancer-causing Mutations
A set of proteins involved in the body’s natural defenses produces a large number of mutations in human DNA, according to a study led by researchers at the National Institutes of Health. The findings, published in Nature Genetics, suggest that these naturally produced mutations are just as...
American Ginseng Improves Cancer-related Fatigue
In a collaborative phase III trial of the North Central Cancer Treatment Group and Mayo Clinic reported in Journal of the National Cancer Institute by Debra L. Barton, RN, PhD, of the Mayo Clinic, and colleagues, patients with cancer-related fatigue were treated with Wisconsin ginseng (a common...
Molecular Relative of p53 Tumor-suppressor Protein also Helps Cancer Cells Thrive
The protein TAp73 shares extensive common gene sequences with the tumor-suppressor protein p53, and previous studies have suggested that it may function similarly to p53 to prevent tumor formation. However, unlike p53, the most commonly mutated gene in human tumors, TAp73 is rarely mutated and is...
Most Commonly Used Ovarian Cancer Cell Lines Do Not Resemble Ovarian Cancer
Researchers from Memorial Sloan-Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer. Their findings are the result of a detailed review of genomic data that recently became publicly...
Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC
In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final...
Obinutuzumab Shows Activity in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma and Indolent Non-Hodgkin Lymphoma
Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices ...
Colorectal Cancer Survivors Face Increased Risk of Developing Subsequent Cancers of Different Types
According to a new study, colorectal cancer survivors face an increased risk of developing subsequent primary cancers, particularly second colorectal cancers and small intestinal cancers. These findings, published online in Cancer, may help in the development of screening guidelines for patients...
Whole-exome Sequencing of the NCI-60 Cell Line Panel Provides a Genomic Resource for Cancer Biology and Systems Pharmacology
The NCI-60 cell lines, which represent cancers of lung, colon, brain, ovary, breast, prostate, and kidney as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As...
Nerves Play Key Role in Triggering Prostate Cancer and Promoting Metastases
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that nerves play a critical role in both the development and spread of prostate tumors. Their findings, using both a mouse model and human prostate tissue, may lead to new ways to predict the aggressiveness of...
FDA Approves Afatinib for EGFR-mutant Late-stage Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved the tyrosine kinase inhibitor afatinib (Gilotrif) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21...
Study Confirms Link Between High Blood Levels of Omega-3 Fatty Acids and Increased Risk of Aggressive Prostate Cancer
A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer. Study Details Published online in the Journal of the National Cancer Institute, the...
Factors Influencing Delay in Breast Cancer Treatment Differ for African American and White Women
Different factors influence delay between diagnosis and first course of treatment for breast cancer for African American and white women, according to a recently published study in Cancer Epidemiology, Biomarkers & Prevention. The study used data from the Carolina Breast Cancer Study (CBCS)...
New Drug Application Submitted for Ibrutinib in the Treatment of Two B-cell Malignancies
Pharmacyclics, Inc, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and...
Soy Protein Supplementation Does Not Reduce Risk of Prostate Cancer Recurrence after Radical Prostatectomy
Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10...
Nearly Half of Sarcoma Surgeries Performed by Nononcologists
Nearly half the surgical procedures for sarcoma done at 85 academic medical centers were performed by surgeons untrained in oncology, according to national data analyzed by researchers from the University of California Davis Medical Center, Sacramento. Orthopedic oncologists and surgical...
Afatinib Prolongs Progression-free Survival Compared with Cisplatin plus Pemetrexed in EGFR-mutant Advanced Lung Adenocarcinoma
Afatinib is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has exhibited broad-spectrum activity against EGFR mutations in preclinical studies. A phase II study of afatinib in EGFR-mutation positive lung adenocarcinoma showed...
Aspirin May Help Prevent Cancer in Patients with Barrett’s Esophagus
Although aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce cancer mortality by 20%, exactly why these drugs reduce the number of cancer incidences and deaths is not known. Now, a small longitudinal study of 13 patients with Barrett’s esophagus is...
Volumetric Growth Rate of Small Colorectal Polyps on CT Colonography May Be Useful Risk Marker
The growth rates and clinical importance of small colorectal polyps have not been well established. In a study reported in Lancet Oncology, Perry J. Pickhardt, MD, of the University of Wisconsin School of Medicine and Public Health, and colleagues found that volumetric growth rate on computed...
African Americans with Chronic Lymphocytic Leukemia Do Not Live as Long as Caucasians, Despite Equal Care
A new analysis has found that among patients with chronic lymphocytic leukemia (CLL), African Americans more commonly present with advanced disease and tend to have shorter survival times than Caucasians despite receiving the same care. The results, published early online in Cancer, suggest that...
Two HIV Patients Show No Signs of Disease Following Bone Marrow Transplants for Hodgkin Lymphoma
Timothy Henrich, MD, Associate Physician in the Division of Infectious Disease at Brigham and Women’s Hospital in Boston, reported that two patients with long-standing HIV infections have no detectable levels of the disease in their blood cells, even though they stopped taking their...
Single Men, Smokers at Higher Risk for Oral HPV Infection
Smokers and single men are more likely to acquire oncogenic oral human papillomavirus (HPV), according to new results from the HPV Infection in Men (HIM) Study. Researchers from Moffitt Cancer Center, the National Cancer Institute, Mexico, and Brazil also reported that newly acquired oral HPV...
FDA Grants Priority Review to Obinutuzumab in CLL and Pertuzumab in Neoadjuvant Therapy for HER2-positive Early-stage Breast Cancer
Two drugs were given Priority Review designation by FDA earlier this week. Obinutuzumab (GA101) was granted Priority Review for the treatment of chronic lymphocytic leukemia (CLL), based on final stage 1 data from the pivotal CLL11 trial. FDA also granted Priority Review to a pertuzumab (Perjeta)...
Novel Drug Combination Shows Activity in Recurrent Ovarian Cancer
A novel pairing of two investigational cancer drugs in patients with recurrent ovarian cancer showed promising activity and had manageable toxicities, according to a phase I trial published online in the European Journal of Cancer. The combination of the poly(ADP-ribose) polymerase (PARP)...
Biomarker Predicts Risk of Breast Cancer Recurrence after Tamoxifen Treatment
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. In a report published online in the Journal...
Oral Apixaban Lowers Rates of Major Bleeding in Patients with Acute Venous Thromboembolism
Single-agent apixaban (Eliquis) may simplify the treatment of patients with acute venous thromboembolism, according to a new study published online in The New England Journal of Medicine. In the phase III AMPLIFY trial, the oral factor Xa inhibitor anticoagulant was found to be as effective as ...
Acupuncture May Reduce Arm Lymphedema in Patients with Breast Cancer
Arm lymphedema affects approximately 30% of breast cancer survivors, with rates increasing with longer follow-up and cases presenting well beyond the active treatment period. Lymphedema is observed even with use of less-invasive surgical techniques for staging, and risk is further increased by such ...
Scientists Develop Mathematical Model to Predict Cancer Cells’ Resistance to Therapy
New research using mathematical models of different types of cancer—including melanoma, pancreatic, and colorectal—to determine the evolutionary dynamics of lesions in response to treatment is revealing why and how cancer cells resist targeted therapies. The study by Ivana Bozic, PhD,...
Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC
In a phase III trial reported by Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients with advanced...
Novel Research Method May Lead to Tailored Treatments for Late-stage Prostate Cancer
A study using a novel “co-clinical” approach that integrates data from hundreds of genetically engineered mouse models with clinical data from tissue samples of hundreds of patients with castration-resistant prostate cancer, has identified several molecular pathways underlying...
Survival Rates for Patients with Burkitt’s Lymphoma Improve, Especially among Young Adults
Although Burkitt’s lymphoma remains one of the most highly aggressive forms of B-cell non-Hodgkin lymphoma and is associated with human immunodeficiency virus (HIV) infection, a recent study published in Blood has found a marked improvement in patient survival over the past decade, especially ...
Study Reveals Abstracts with Financial Conflicts of Interest Have Higher Meeting Prominence, Better Peer Review Score
Beverly Moy, MD, Clinical Director of the Breast Oncology Program at Massachusetts General Hospital, and colleagues recently analyzed the relationship between declaration of financial conflicts of interest and "research prominence" for abstracts presented at American Society of Clinical Oncology...
BRAF Mutation Status May Have Effect on Benefit of Aspirin Use for Patients with Colorectal Cancer
In two large studies, the association between aspirin use and risk of colorectal cancer was affected by BRAF mutation status, with regular aspirin use associated with a lower risk of BRAF wild-type colorectal cancer but not with risk of BRAF-mutated cancer. The findings, published today in JAMA,...
Use of Advanced Treatment Technologies Increases among Men at Low Risk of Dying from Prostate Cancer
Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy (IMRT) and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these...
Lugano 2013: Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion
The 17p deletion in chronic lymphocytic leukemia (CLL) is associated with worse outcome in patients receiving standard chemotherapy. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown durable antitumor activity in high-risk CLL. Adrian Wiestner, MD, PhD, of the National...
New Study Finds AICR Recommendations Cut Breast Cancer Risk
Postmenopausal women who follow at least five Recommendations for Cancer Prevention from the American Institute for Cancer Research (AICR) cut their risk of developing breast cancer by more than half, compared to those who meet none, suggests a new study that adds to previous research showing...
Chemotherapy-induced Neuropathy Has Long-term Effect on Colorectal Cancer Survivors
In a study reported in Journal of Clinical Oncology, Floortje Mols, PhD, of the Center of Research on Psychology in Somatic Diseases, Tilburg University, and colleagues assessed the prevalence and severity of chemotherapy-induced neuropathy and its affect on health-related quality of life in...
BTK Inhibitor Ibrutinib Produces High Response Rate in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase (BTK), a mediator of the B-cell receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University...
Two Bills before Congress Aim to Fight Breast Cancer and End Disparities in Care
Members of Congress are considering two bills that could advance cures for breast cancer and provide better education for women grappling with decisions about their treatment options. Accelerating the End of Breast Cancer Act Accelerating the End of Breast Cancer Act of 2013 (S. 865/H.R. 1830)...
Researchers Identify and Map Signaling Pathway from EGFR to MCM7 Protein
Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point. A team led by scientists at The University of Texas MD Anderson Cancer Center reported the tie between...
Deep Sequencing Accurately Predicts Prolonged Survival in Multiple Myeloma Patients
A study by the Spanish Myeloma Group comparing the prognostic value of traditional response criteria and minimal residual disease measurement in patients with multiple myeloma found that a sequencing-based method called LymphoSIGHT and multiparameter flow cytometry analysis both accurately...
Virus Combination Effective Against Temozolomide-resistant Glioblastoma Multiforme
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to new research published in Neuro-Oncology. Study lead author Peter A. Forsyth, MD, Chair of the Neuro-oncology Program at Moffitt ...
